Semi-synthetic Fc-peptide conjugation strategy enables prolonged circulation and retained biological activity

Many therapeutic peptides, despite their high target specificity and ability to modulate 'undruggable' targets, suffer from extremely short plasma half-lives, severely limiting their clinical utility. Current solutions often involve recombinant fusion to the Fc region of IgG antibodies, which effectively prolongs systemic half-life. However, this recombinant approach restricts the incorporation of non-proteinogenic features like non-natural amino acids, cyclic peptides, or oligonucleotides, which can significantly enhance stability and biological activity. A method to combine Fc-fusion with these advanced chemical features is a critical unmet need in peptide drug development.

Researchers developed a novel semi-synthetic strategy to generate Fc-peptide conjugates, specifically designed to overcome the limitations of recombinant methods. The approach involved the design, synthesis, and bioconjugation of functionalized disulfide re-bridging linkers. This methodology allowed for the efficient attachment of peptides, including those with non-proteinogenic features, to the Fc region. An Fc-peptide conjugate was then generated using this strategy and subsequently evaluated for its biological activity in vitro and its circulation profile in vivo to confirm the efficacy of the conjugation method.

The novel semi-synthetic strategy successfully produced Fc-peptide conjugates capable of incorporating non-proteinogenic features, a key limitation of traditional recombinant methods. The primary finding was the successful generation of these conjugates while preserving the peptide's inherent therapeutic efficacy. Specifically, the Fc-peptide conjugate demonstrated retained biological activity in vitro, confirming that the chemical conjugation via functionalized disulfide re-bridging linkers did not impair the peptide's ability to interact with its target or elicit a biological response. This is a critical validation step, as half-life extension methods must not compromise the drug's fundamental function.

Furthermore, the conjugates achieved prolonged circulation in vivo, directly addressing the challenge of short plasma half-life that plagues many therapeutic peptides. This extended systemic presence is crucial for reducing dosing frequency and improving patient compliance and therapeutic outcomes. The abstract highlights that this method allows for the simple and efficient generation of these conjugates, suggesting a robust and scalable process. While specific quantitative data on the degree of half-life extension or the precise percentage of activity retained were not provided, the qualitative success in both aspects validates the utility of this semi-synthetic approach for overcoming current limitations in peptide drug development.